Development History
2025
2024
2023
2022
2021
2020
2019
2018
2017
2025
-
• Nearly 200 hospitals were admitted with naltrexone hydrochloride implants
• The Phase II clinical trial of naltrexone hydrochloride implant for alcohol use disorders has been successfully completed
• Phase III clinical trial of naltrexone hydrochloride implant for alcohol use disorders indication officially launched
• The clinical trial of naltrexone hydrochloride implant for opioid relapse prevention has officially started after its launch
2024
-
• The implant of naltrexone hydrochloride has been approved for market by the China National Medical Products Administration
• Phase II clinical trial of naltrexone hydrochloride implant for alcohol use disorders indication launched
• Shankang Pharmaceutical was honored as one of the "Top Ten Emerging Enterprises in Pingshan District for 2024"
2023
-
• The implant of naltrexone hydrochloride has passed GMP on-site inspection and development site inspection
• Shankang Pharmaceutical was awarded the title of "Shenzhen Specialized, Refined, Unique and New Small and Medium sized Enterprise"
2022
-
• Complete the corporate shareholding system reform
• Shankang Pharmaceutical Research Institute was officially established and listed
• Shankang Pharmaceutical was honored as one of the "Top Ten Emerging Enterprises in Pingshan District in 2022"
2021
-
• In April, naltrexone hydrochloride implant was listed as a breakthrough therapeutic drug by the National Medical Products Administration
• In August, we completed a Series B financing of 183 million yuan and introduced institutions such as Shenzhen Guoke, Huajin Capital, and Xiaoxiang Zhiyi
2020
-
• The Phase II clinical trial of naltrexone hydrochloride implant has been successfully completed
• Completed a Series A financing of 120 million yuan, with investors from institutions such as Shenzhen Venture Capital, Xiaoxiang Capital, and Beijing Jingchou Biotechnology
2019
-
• Phase II clinical trial of naltrexone hydrochloride implant has been completed
• Employee stock option incentive plan launched, distributing the first batch of options
2018
-
• Phase II clinical trial of naltrexone hydrochloride implant officially launched
• Initiate the industrialization construction of naltrexone hydrochloride implants
2017
-
• Shankang Pharmaceutical settled in Pingshan District, Shenzhen and was officially established.
Corporate Culture
Our Vision
A leading enterprise in the field of addiction treatment with ultra long acting drug delivery technology as its core.
